Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,486.22 +8.32 (+0.15%) Dow
39,220.23 +92.43 (+0.24%) Nasdaq
17,851.15 +45.99 (+0.26%) Bitcoin USD
62,028.07 +292.21 (+0.47%) CMC Crypto 200
1,294.80 +28.66 (+2.26%)
NTRA Jan 2025 70.000 call
| Previous close | 42.60 |
| Open | 42.60 |
| Bid | 43.00 |
| Ask | 47.50 |
| Strike | 70.00 |
| Expiry date | 2025-01-17 |
| Day's range | 42.60 - 42.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
Business WireNatera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
AUSTIN, Texas, June 27, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer.
GuruFocus.comInsider Selling: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
On June 17, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), executed a sale of 6,105 shares of the company. The transaction was filed on June 18, 2024, as reported in the SEC Filing. Following this transaction, the insider now owns 213,351 shares of Natera Inc.
Business WireNatera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
AUSTIN, Texas, June 17, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.
